English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/199675
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Identification of tumor-associated antigens with diagnostic ability of colorectal cancer by in-depth immunomic and seroproteomic analysis

Other TitlesRunning title: CRC biomarker identification by seroproteomic analysis
AuthorsGarranzo Asensio, María; San Segundo-Acosta, Pablo; Povés, Carmen; Fernandez-Aceñero, M. Jesús; Martínez-Useros, Javier; Montero-Calle, Ana; Solís-Fernández, Guillermo; Sánchez-Martínez, María Cruz; Rodríguez, Nuria ; Cerón, María Ángeles; Fernández-Díez, Servando; Domínguez, Gemma; Ríos, Vivian de los ; Peláez-García, Alberto ; Guzmán-Aránguez, Ana I.; Barderas, Rodrigo
Issue Date1-Mar-2020
CitationJournal of Proteomics 214: 103635 (2020)
AbstractColorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer related death worldwide. Its diagnosis at early stages would significantly improve the survival of CRC patients. The humoral immune response has been demonstrated useful for cancer diagnosis, predating clinical symptoms up to 3years. Here, we employed an in-depth seroproteomic approach to identify proteins that elicit a humoral immune response in CRC patients. The seroproteomic approach relied on the immunoprecipitation with patient-derived autoantibodies of proteins from CRC cell lines with different metastatic properties followed by LC-MS/MS. After bioinformatics, we focused on 31 targets of CRC autoantibodies. After WB and IHC validation, ERP44 and TALDO1 showed potential to discriminate disease-free and metastatic CRC patients, and time to recurrence of CRC patients in stage II. Using plasma samples of 30 healthy individuals, 28 premalignant individuals, and 32 CRC patients, nine out of 13 selected targets for seroreactive analysis showed significant diagnostic ability to discriminate either CRC patients or premalignant subjects from controls. Our results suggest that the here defined panel of CRC autoantibodies and their target proteins should be included in CRC blood-based biomarker panels to get a clinically useful blood-based diagnostic signature for CRC detection. SIGNIFICANCE: Colorectal cancer is one of the deadliest cancer types mainly due to its late diagnosis. Its early diagnosis, therefore, is of great importance since it would significantly improve the survival of CRC patients. In our work, the in-depth seroproteomic analysis of colorectal cancer using isolated IgGs from colorectal cancer patients and controls and protein extract of colorectal cancer cells provide the identification of valuable biomarkers with diagnostic and prognostic ability of the disease.
Description48 p.-1 graph. abst.-5 fig.-2 tab.-2 fig supl.-6 tab. supl.
Publisher version (URL)https://doi.org/10.1016/j.jprot.2020.103635
Appears in Collections:(IIBM) Artículos
(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Journal of Proteomics-Garranzo-Asensio-2020.pdf Embargoed until March 1, 2021488,25 kBAdobe PDFThumbnail
View/Open    Request a copy
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.